Pfizer, the world’s largest drug company, is going to try its hand at picking biotech stocks.

The New York pharma giant has set aside up to $500 million that it will invest in publicly traded companies with drugs in the clinic. Pfizer would take non-controlling stakes, with a focus on companies with small to medium market values. The program, called the Pfizer Breakthrough Growth Initiative, would give companies access to the company’s scientists, clinicians, and manufacturing experts, if they want it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Has Pfizer “hand picked” any or is it waiting for companies to approach it with projects?

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy